FUNDAMENTALS
EdgeFII/DII
SUNPHARMASUN Pharmaceutical Industries
₹1,884.90-0.79%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
SUNPHARMANSE · EquityPharmaceuticals

SUN Pharmaceutical Industries

ISIN
INE044A01036
Instrument key
NSE_EQ|INE044A01036
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹1,884.90-15.10 · -0.79%
Day rangecircuit ₹1,696.50 – ₹2,073.30
1,883.00
1,910.00

as of 21/11/2026, 3:25:29 pm

Open
₹1,898.00
Day high
₹1,910.00
Day low
₹1,883.00
Prev. close
₹1,900.00
Volume
19.16 L
VWAP
₹1,892.13

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

5 years · weekly candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 5Y
+138.40%
790.65 → 1,884.90
Period high
₹2,046.90
27/7/2026
Period low
₹733.70
6/12/2021
From high
-7.91%
+156.90% from low
Avg volume
1.21 Cr
315.85 Cr total
Volatility · ann.
19.7%
262 candles · 135 up / 127 down
16 Nov 2026O 1,885.00H 1,914.80L 1,856.80C 1,884.90Vol 83.27 L
SMA 20SMA 50Averages need 50 candles before they begin
Candle data262 rows of open, high, low, close and volumeShowHide
16 Nov 20261,885.001,914.801,856.801,884.90-0.01%58.0083.27 L
9 Nov 20261,915.001,943.901,869.801,880.00-1.83%74.1098.91 L
2 Nov 20261,770.001,929.401,722.001,915.00+8.19%207.401.83 Cr
26 Oct 20261,752.401,855.001,726.201,777.70+1.44%128.801.05 Cr
19 Oct 20261,758.801,768.901,719.101,748.00-0.61%49.8059.89 L
12 Oct 20261,764.301,778.001,725.501,758.80-0.31%52.5070.40 L
5 Oct 20261,785.001,804.201,745.001,760.00-1.40%59.2068.71 L
28 Sept 20261,844.001,865.001,792.601,801.00-2.33%72.4087.47 L
21 Sept 20261,832.201,891.501,832.201,852.20+1.09%59.3069.25 L
14 Sept 20261,854.601,877.201,828.001,837.30-0.93%49.2070.82 L

Historical price and volume data · Showing 1–10 of 262

1 / 27

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

41.17
Company
41.17
Sector
-45.02

Worse than sector by 191%

P/B

Price ÷ book value per share

5.07
Company
5.07
Sector
4.21

Worse than sector by 20%

ROA

Net income ÷ total assets

9.61%
Company
9.61%
Sector
1.19%

Better than sector by 708%

ROE

Net income ÷ shareholders' equity

13.79%
Company
13.79%
Sector
-0.4%

Better than sector by 3547%

ROCE

EBIT ÷ capital employed

18.65%
Company
18.65%
Sector
15.44%

Better than sector by 21%

Quick Ratio

Liquid assets ÷ current liabilities

2.31
Company
2.31
Sector
4.8

Worse than sector by 52%

EV/EBITDA

Enterprise value ÷ EBITDA

23.87
Company
23.87
Sector
22.86

Worse than sector by 4%

04/Business

About the company

Sector: Pharmaceuticals

Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.

Sector market cap (INR)
₹4,52,299 Cr

reported in crore

Sector market cap (USD)
$50.26B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹16,716 Cr
+4.32% vs Jun 2026
Net profit · Sep 2026
₹2,002 Cr
-31.24% vs Jun 2026
Operating margin
18.9%
was 25.6%
Revenue CAGR · 4p
1.3%
profit -16.2% · op -9.2%
Filed order
Revenue16,71616,02415,07016,099
Revenue growthreported4.3%6.3%-6.4%—
Operating profit3,1594,0993,5514,227
Operating profit growthreported-22.9%15.4%-16.0%—
Operating marginderived18.9%25.6%23.6%26.3%
Net profit2,0022,9112,7243,401
Net profit growthreported-31.2%6.9%-19.9%—
Net marginderived12.0%18.2%18.1%21.1%
EPS — basic₹/share, annual——47.80—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue58,46252,57848,49743,886
Other Income3,2122,1511,390635
Total Revenue61,67454,72949,88744,520
Total Expenses45,24840,29938,30534,940
Profit Before Tax15,11913,75211,0889,408
Tax3,5542,7721,439848
Profit After Tax11,56510,9809,6488,561
EPS - Basic47.8045.6039.9035.30
EPS - Diluted47.8045.6039.9035.30

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹1.09L Cr
+18.12% YoY
Total liabilities
₹24,905 Cr
Net worth
₹83,880 Cr
Liabilities ÷ assets
22.9%
lower means a lighter balance sheet
Filed order
Total assets1,08,78592,10185,50080,744
Total liabilities24,90519,61518,37421,428
Net worthderived83,88072,48667,12659,315
Liabilities ÷ assetsderived22.9%21.3%21.5%26.5%
Asset growthderived18.1%7.7%5.9%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets44,92539,50742,06740,882
Current Assets63,86052,59443,43339,862
Total Assets1,08,78592,10185,50080,744
Current Liabilities22,62218,19416,98419,906
Net Current Asset41,23834,40026,44919,956
Non-Current Liabilities2,2831,4201,3901,522
Equity Capital83,88072,48667,12659,315
Total Equity & Liabilities1,08,78592,10185,50080,744

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹12,419 Cr
-11.75% YoY
Investing
-₹11,344 Cr
Financing
-₹2,513 Cr
Free cash flow
₹1,075 Cr
operating + investing
Filed order
Operating activities12,41914,07212,1354,959
Operating changereported-11.8%16.0%144.7%—
Investing activities-11,344-5,306-690-7,944
Investing changereported-113.8%-668.8%91.3%—
Financing activities-2,513-7,906-6,7102,376
Financing changereported68.2%-17.8%-382.4%—
Net cash flowderived-1,4378604,735-608
Free cash flowoperating + investing1,0758,76611,445-2,984

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax15,11913,75211,0889,408
Income before WC changes16,00114,87212,64212,131
Change in Assets-2,271-1,845568-2,371
Change in Liabilities1,0031,522494-3,291
Change in WC-1,268-3241,062-5,662
Cash flow from Operations12,41914,07212,1354,959
Cash flow from Investing-11,344-5,306-690-7,944
Cash flow from Financing-2,513-7,906-6,7102,376
Total Cash Flow-1,4378604,735-608
Cash (Start of the year)10,2699,2864,6244,508
Cash (End of the year)9,77110,2699,2864,624

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
52.68%
-1.80 pts QoQ
FII
14.36%
-0.17 pts QoQ
DII (other)
9.26%
-0.08 pts QoQ
Mutual funds
13.01%
+0.17 pts QoQ
Retail & others
10.70%
+1.89 pts QoQ
Filed order
Promoters52.7%54.5%54.5%54.5%
FII14.4%14.5%15.9%16.1%
DII (other)9.3%9.3%9.2%8.7%
Mutual funds13.0%12.8%12.0%12.1%
Retail & others10.7%8.8%8.5%8.6%
Promoters — QoQ changepts, derived-1.8%0.0%0.0%—
FII — QoQ changepts, derived-0.2%-1.4%-0.2%—
DII (other) — QoQ changepts, derived-0.1%0.2%0.4%—
Mutual funds — QoQ changepts, derived0.2%0.9%-0.1%—
Retail & others — QoQ changepts, derived1.9%0.3%-0.1%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹5.00500.0%07 Jul 202607 Jul 202622 May 2026
DividendInterim₹11.001100.0%05 Feb 202605 Feb 202620 Jan 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
DRREDDYDR. Reddy S LaboratoriesPharmaceuticals₹1,390.20-0.76%8.31 L₹1,16,145 Cr$12.90B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.